COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 7 of 53 for:    Developmental Disabilities | ( Map: Indiana, United States )

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00080145
Recruitment Status : Completed
First Posted : March 25, 2004
Last Update Posted : August 16, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Denis Sukhodolsky, Yale University

Brief Summary:
This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.

Condition or disease Intervention/treatment Phase
Child Development Disorders, Pervasive Drug: Risperidone Behavioral: Behavior Therapy Not Applicable

Detailed Description:

PDD can be a profoundly disabling condition across social, emotional, and academic domains. Safe and effective treatments for PDD are needed.

Participants are randomly assigned to receive either risperidone plus parent management training or risperidone alone for 24 weeks. Participants who show deterioration at Week 4 will be offered an alternative mediation treatment, aripiprazole. These participants will remain in their original treatment group (either med alone or med plus parent management training). After 6 months of treatment (Week 24), participants who respond to their treatment will be gradually discontinued from their medication treatment to learn if the response can be sustained without continued medication treatment (This phase of the study was ended in Nov. 2006) Adaptive and behavioral outcomes are assessed during the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder
Study Start Date : February 2004
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Risperidone

Arm Intervention/treatment
Active Comparator: risperidone plus parent management training Drug: Risperidone
Behavioral: Behavior Therapy
Active Comparator: risperidone only Drug: Risperidone

Primary Outcome Measures :
  1. Home Situations Questionnaire [ Time Frame: Week 24 ]
  2. Vineland Daily Living Skills Scale [ Time Frame: Week 24 ]

Secondary Outcome Measures :
  1. Irritability subscale-Aberrant Behavioral Checklist [ Time Frame: Week 24 ]
  2. Clinical Global Impressions-Improvement (CGI-I) [ Time Frame: Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Autistic Disorder, Asperger's Disorder, or Pervasive Developmental Disorder not otherwise specified
  • Weight > 30 lbs
  • IQ >= 35 or mental age of at least 18 months

Exclusion Criteria:

  • Psychotic Disorder
  • History of intolerance or nonresponse to risperidone
  • Pregnancy
  • History of neuroleptic malignant syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00080145

Layout table for location information
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Yale University
National Institute of Mental Health (NIMH)
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Denis Sukhodolsky, Principal Investigator, Yale University Identifier: NCT00080145    
Other Study ID Numbers: U10MH066764 ( U.S. NIH Grant/Contract )
U10MH066764 ( U.S. NIH Grant/Contract )
U10MH066766 ( U.S. NIH Grant/Contract )
U10MH066768 ( U.S. NIH Grant/Contract )
First Posted: March 25, 2004    Key Record Dates
Last Update Posted: August 16, 2013
Last Verified: August 2013
Keywords provided by Denis Sukhodolsky, Yale University:
Autistic Disorder
Asperger Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Developmental Disabilities
Child Development Disorders, Pervasive
Autistic Disorder
Pathologic Processes
Autism Spectrum Disorder
Neurodevelopmental Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents